RTW Investments LLC
RTW Investments invests with innovative health care companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed RTW Investments LLC Information
Geographic Data
Address: 250 W 55th St
City: New York
State: NY
Zip: 10019
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
2,603,527Website Global Rank
6,805Website Monthly Traffic
Twitter Followers
Description
RTW Investments is a provider of investment management services for the healthcare industry.
Contact Phone:
+16465976982
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 8/2021 | Rocket Pharmaceuticals | Post-IPO Equity | 26.4M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 6/2021 | Umoja Biopharma | Series B | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2021 | Renovacor | Post-IPO Equity | 0 |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 3/2021 | UroGen Pharma | Post-IPO Equity | 75M |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 9/2015 | AveXis | Series D | 65M |
| 4/2021 | GH Research | Series B | 125M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 3/2021 | Visus Therapeutics | Series A | 36M |
| 12/2020 | Nuance Biotech | Series D | 181M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 7/2015 | Immunocore | Series A | 320M |
| 1/2019 | Magnolia Medical Technologies | Series C | 0 |
| 1/2019 | Beta Bionics | Series B | 63M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 2/2023 | Oricell Therapeutics | Series B | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 1/2019 | Attune Pharmaceuticals | Series B | 23M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 3/2020 | Immunocore | Series B | 0 |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 12/2017 | Orchard Therapeutics | Series B | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
| 9/2020 | NiKang Therapeutics | Series B | 50M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 5/2019 | Pulmonx | Series G | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 8/2017 | ARMO BioSciences | Series C | 0 |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 6/2021 | Alcyone Therapeutics | Venture Round | 23M |
| 7/2021 | Jixing Pharmaceuticals | Series B | - |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 3/2021 | Tenaya Therapeutics | Series C | 106M |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
